Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 15097966.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Ten patients with malignant melanoma and phototoxic reactions under dacarbazine or 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DTIC) chemotherapy were investigated. All patients available for testing showed increased ultraviolet A-sensitivity (n = 5); patch testing revealed no type IV allergies (n = 6). In 5 patients intravenous DTIC was replaced by oral temozolomide, and no phototoxicity occurred. Temozolomide may represent an alternative for patients with DTIC-induced phototoxic skin reactions.
Medical subject headings
- Antineoplastic Agents, Alkylating
- Dacarbazine
- Dermatitis, Phototoxic
- Melanoma
- Skin Neoplasms